alexa Pharmacokinetics and Tolerability of Single and Multiple Doses of Desvenlafaxine in Healthy Korean Subjects | OMICS International | Abstract
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Pharmacokinetics and Tolerability of Single and Multiple Doses of Desvenlafaxine in Healthy Korean Subjects

Liang Y1*, Qiu R2, Kim S3, Jang IJ3, Lee WS4, Plotka A5 and Nichols A5

1Pfizer Inc., Groton, CT, USA

2Pfizer Inc., Cambridge, MA, USA

3Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea

4Pfizer Korea Inc., Seoul, Republic of Korea

5Pfizer Inc., Collegeville, PA, USA

Corresponding Author:
Liang Y MS
Senior Associate, Pfizer, 445 Eastern
Point Road-MS8260-2241, Groton, CT 06340, USA
Tel: 860 441 6952
E-mail: [email protected]

Received Date: November 11, 2016; Accepted Date: January 10, 2017; Published Date: January 27, 2017

Citation: Liang Y, Qiu R, Kim S, Jang IJ, Lee WS, et al. (2017) Pharmacokinetics and Tolerability of Single and Multiple Doses of Desvenlafaxine in Healthy Korean Subjects. J Bioequiv Availab 9:341-345. doi: 10.4172/jbb.1000322

Copyright: © 2017 Liang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Racial and ethnic variations in CYP enzyme polymorphisms have been associated with population differences in drug metabolism. This study evaluated the pharmacokinetics of single- and multiple-dose desvenlafaxine in healthy Korean subjects.

Methods: This randomized, double-blind, placebo-controlled, study enrolled 38 healthy Korean adults (aged 18 to 55 years). Subjects received single oral doses of placebo or desvenlafaxine (administered as desvenlafaxine succinate) 50, 100, or 200 mg on day 1, followed by 5 days of once daily dosing on days 4 to 8. Blood samples were collected pre-dose and over 72 h post-dose on days 1 and 8. Plasma desvenlafaxine concentrations were measured using a validated high-performance liquid chromatography tandem mass spectrometry and pharmacokinetic parameters were calculated using non-compartmental method. Tolerability was assessed through adverse event reporting.

Results: For both single-and multiple-dose desvenlafaxine, peak plasma concentration and area under the concentration-time curve increased approximately linearly with dose. For the 4-fold increase in dose from 50 mg to 200 mg desvenlafaxine, area under the concentration-time curve from time 0 extrapolated to infinite time for singledose and area under the concentration-time curve from time 0-24 h for multiple-dose administration increased 4.3- and 4.1-fold, respectively; peak plasma concentration values increased 4.5- and 4.3-fold, respectively. Mean apparent half-life ranged from 10.75-13.49 h across all doses following single and multiple dose administration. Accumulation ratios for area under the concentration-time curve ranged from 1.478 to 1.669 (peak plasma concentration, 1.488- 1.578). No serious or severe adverse events were reported.

Conclusion: The pharmacokinetics of multiple-dose desvenlafaxine 50-200 mg was linear and was able to be predicted from single-dose pharmacokinetics in Korean subjects. Pharmacokinetic parameters were similar to values previously observed in other racial/ethnic populations. There were no new safety findings for desvenlafaxine.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7